Dr. Parsons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-1992Fax+1 617-632-1930
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- Johns Hopkins UniversityResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2015 - 2026
MD State Medical License 2013 - 2015- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Start of enrollment: 2017 Oct 25
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 3 citationsPrevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel
Journal of Clinical Oncology. 2024-11-01 - Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer.Shoshana M Rosenberg, Yue Zheng, Katheryn Santos, Elizabeth Riley, Hugh Wallace Meadows
Breast Cancer Research and Treatment. 2024-10-21 - Ductal Carcinoma In Situ.Brittany L Bychkovsky, Sara Myers, Laura E G Warren, Pietro De Placido, Heather A Parsons
Hematology/oncology Clinics of North America. 2024-08-01
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
Press Mentions
Evolving Conversations in HER2+ Oligometastatic Breast Cancer ManagementSeptember 19th, 2024- STOP-HER2: Stopping Trastuzumab in HER2+ MBCFebruary 9th, 2023
- Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in AdvanceJune 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
